SynDermix AG is pleased to announce the successful completion of the first SIV for the clinical trial of SDX-3101, in preparation for the recruitment of the first patient to the study. (more…)
SynDermix is a Swiss developer of innovative health technologies that focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.
First Site Initiation Visit (SIV) Completed for the Clinical Trial of SDX-3101 in Austria 7 January, 2020 in UpdatesSynDermix AG is pleased to announce the successful completion of the first SIV for the clinical trial of SDX-3101, in preparation for the recruitment of the first patient to the study. (more…)
Collaboration with King’s College London on the Formulation Development of SDX-21 1 July, 2019 in UpdatesSynDermix AG is proud to announce its collaboration with King’s College London for the development of its Nitric Oxide technology. (more…)
AGM 2019: Re-election of Chairman and Board of Directors 11 June, 2019 in UpdatesShareholders approve all proposals put forward by the Board of Directors and re-elect the Chairman and Directors to the board of SynDermix.
(more…)
SDX-31 is an electronic medical device platform based on Precisely Modulated Acoustic Energy™ (PMAE) therapy; a proprietary type of treatment during which digitally controlled acoustic frequencies are generated
SDX-21 is a platform based on an endogenous Nitric Oxide (NO) donor in an easy-to-use formulation, which can be leveraged for the development of drug products or medical devices, depending on the selected indication
SDX-13 is a drug platform based on a novel recombinant plant lectin with positive Phase IIa results in epithelial healing and a favourable safety profile
Together, our executive team, specialist partners and company values combine to sustain ground-breaking health science and process excellence.
SynDermix is a privately funded company. Investors and other account holders, please click here to log in.
